Blog

D-Pharm Ltd.

D Pharm expands Chinese cooperation agreement. The agreement with Wanbang Biopharmaceuticals was extended to a new formulation of D Pharm’s treatment for ischemic stroke
D-Pharm Ltd. (TASE: DPRM) has expanded its commercialization agreement with China’s Wanbang Biopharmaceuticals Ltd. for D Pharm’s leading product, DP-b99 for the treatment of ischemic stroke. D Pharm will receive $7.65 million

Gamida Cell Ltd.

Gamida Cell Completes Enrollment for Phase I/II Study of Second Pipeline Product NiCord® for Hematological Malignancies
 
Gamida Cell , a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company’s second pipeline product.
NiCord is in development as an experimental treatment

Argo Medical Technologies Ltd.

New Era Starts as ReWalk Exoskeleton Technology is Available to Take Home
LONDON–Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use. Claire demonstrated her personal ReWalk™ at the annual International Spinal Cord Society

NanoPass Technologies Ltd.

NanoPass Secures Series B Investment to Accelerate Commercialization of its Intradermal Delivery Products
NanoPass Technologies Ltd., a pioneer in the development and commercialization of painless intradermal (skin) delivery solutions for vaccines and large molecules, announced today it has recently closed a new round of financing, led by Israel HealthCare Ventures (IHCV), a leading healthcare-dedicated venture capital

Orsense Ltd.

OrSense Introduces Glasswing, its Next-Generation, Wireless, Non-Invasive Hemoglobin Monitoring System for Anemia Screening
Cancun, Mexico, July 9, 2012 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced today at the 32nd International Congress of the International Society of Blood Transfusion (ISBT), in Cancun, Mexico, GlasswingTM, its next-generation, wireless, non-invasive hemoglobin (Hb)

OrSense Ltd.

OrSense detects hemorrhage, anemia during pregnancy
Israel’s OrSense , a developer of monitors for non-invasive measurements of various blood parameters, announced successful clinical trial results for anemia screening and hemorrhage detection via non-invasive methods. Dr. Eran Hadar, of the Department of Maternal Fetal Medicine at Rabin Medical Center, said OrSenes’s NBM200 device was as accurate as

Gamida Cell Ltd.

The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma. The results of the StemEx study are expected during the second half of 2012
Jerusalem, Israel, February 13, 2012 — Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally

D-Pharm Ltd.

D-Pharm announces expected date of interim report for the DP-b99 Acute Ischemic Stroke Study, MACSI
D-Pharm Ltd., (TASE: DPRM) announced today that the interim report for the DP-b99 MACSI study is expected in February, 2012. The report will be based on the futility analysis of the data obtained from first 350 patients that complete the follow

OrSense Ltd.

OrSense’s Non-Invasive Hemoglobin Measurement System for Pre-Donation Screening of Anemia Delivers Superior Clinical Value Compared to Current MethodsRepresentatives of three hospitals and Red Cross blood donation centers will present data on OrSense’s non-invasive hemoglobin screening system at AABB
NES ZIONA, Israel, Oct 20, 2011  — OrSense Ltd., developer of monitors for non-invasive measurements of various blood